These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6403982)

  • 1. C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease.
    André C; Descos L; Vignal J; Gillon J
    Scott Med J; 1983 Jan; 28(1):26-9. PubMed ID: 6403982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease].
    Vucelić B; Krznarić Z; Sentić M; Milicić D; Korać B; Cvorisćec D; Stavljenić A
    Lijec Vjesn; 1990; 112(9-10):281-4. PubMed ID: 2093781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein and monitoring the activity of Crohn's disease.
    Filik L; Dagli U; Ulker A
    Adv Ther; 2006; 23(4):655-62. PubMed ID: 17050508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenteric blood flow is related to disease activity and risk of relapse in Crohn's disease: a prospective follow-up study.
    Ludwig D; Wiener S; Brüning A; Schwarting K; Jantschek G; Stange EF
    Am J Gastroenterol; 1999 Oct; 94(10):2942-50. PubMed ID: 10520849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
    Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal permeability test as a predictor of clinical course in Crohn's disease.
    D'Incà R; Di Leo V; Corrao G; Martines D; D'Odorico A; Mestriner C; Venturi C; Longo G; Sturniolo GC
    Am J Gastroenterol; 1999 Oct; 94(10):2956-60. PubMed ID: 10520851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease.
    Brignola C; Campieri M; Bazzocchi G; Farruggia P; Tragnone A; Lanfranchi GA
    Gastroenterology; 1986 Dec; 91(6):1490-4. PubMed ID: 3770373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome.
    Lahiff C; Safaie P; Awais A; Akbari M; Gashin L; Sheth S; Lembo A; Leffler D; Moss AC; Cheifetz AS
    Aliment Pharmacol Ther; 2013 Apr; 37(8):786-94. PubMed ID: 23432394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum acute phase proteins for determining disease activity of ulcerative colitis and Crohn disease].
    Vucelić B; Milicić D; Krznarić Z; Korać B; Sentić M; Hadzić N; Stavljenić A; Cvorisćec D
    Acta Med Austriaca; 1991; 18(4):100-5. PubMed ID: 1722373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of C-reactive protein with activity of Crohn's disease].
    Yang CH; Chen XY; Yang F; Ran ZH; Liu WZ; Xiao SD
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1253-5. PubMed ID: 16796884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.